| 纯度 | > 95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | ARF6 |
| Uniprot No | P62330 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-175aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGKVLSKIFGNKEMRILMLGLDAAGKTTIL YKLKLGQSVTTIPTVGFNVETVTYKNVKFNVWDVGGQDKIRPLWRHYYTG TQGLIFVVDCADRDRIDEARQELHRIINDREMRDAIILIFANKQDLPDAM KPHEIQEKLGLTRIRDRNWYVQPSCATSGDGLYEGLTWLTSNYKS |
| 预测分子量 | 22 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ARF6重组蛋白的3篇参考文献示例(注：文献信息为模拟生成，仅供参考)：
---
1. **文献名称**: *ARF6 regulates tumor invasion and metastasis through cytoskeletal remodeling*
**作者**: D'Souza-Schorey C, Chavrier P
**摘要**: 该研究通过重组ARF6蛋白的体外实验，揭示了ARF6在激活GTP依赖的细胞骨架重组中的作用，证明其通过调控膜运输和肌动蛋白动力学促进肿瘤细胞的侵袭和转移。
---
2. **文献名称**: *Recombinant ARF6 expression and purification for functional GTPase assays*
**作者**: Casanova JE, et al.
**摘要**: 文章描述了在大肠杆菌系统中高效表达和纯化重组ARF6蛋白的方法，并验证了其GTP结合和水解活性，为ARF6的体外酶学及互作研究提供了技术基础。
---
3. **文献名称**: *ARF6-mediated endocytic recycling regulates cell polarity and migration*
**作者**: Santy LC, et al.
**摘要**: 利用重组ARF6蛋白进行体外膜结合实验，发现ARF6通过调控内吞循环途径影响细胞极性信号通路，进而协调细胞定向迁移过程。
---
(注：如需真实文献，建议通过PubMed或Google Scholar搜索关键词“ARF6 recombinant protein”获取。)
ADP-ribosylation factor 6 (ARF6) is a small GTPase belonging to the ARF family, which plays critical roles in regulating membrane trafficking, cytoskeletal reorganization, and cellular signaling. As a molecular switch, ARF6 cycles between an inactive GDP-bound state and an active GTP-bound state, controlled by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). It is ubiquitously expressed and primarily localized to the plasma membrane and endosomal compartments, where it governs processes like endocytosis, exocytosis, and recycling of membrane components. ARF6 is also implicated in cell migration, adhesion, and cytokinesis by modulating actin dynamics and membrane-cytoskeleton interactions.
Recombinant ARF6 proteins are engineered to study its biochemical and structural properties in vitro. Typically produced in bacterial (e.g., E. coli) or mammalian expression systems, these purified proteins retain the conserved GTP-binding domain, effector-interacting regions, and post-translational modification sites (e.g., myristoylation at the N-terminus for membrane association). Researchers often generate constitutively active (GTP-bound, Q67L mutant) or dominant-negative (GDP-bound, T27N mutant) variants to dissect ARF6’s regulatory mechanisms.
ARF6 dysregulation is linked to pathological conditions, including cancer metastasis, neurological disorders, and viral infections. For example, elevated ARF6 activity promotes tumor invasion by enhancing integrin trafficking and invadopodia formation. Recombinant ARF6 facilitates drug screening, interaction assays (e.g., with ARF-GEFs/GAPs), and structural studies (e.g., crystallography) to identify therapeutic targets. Recent advances also explore its role in extracellular vesicle biogenesis and immune responses. Overall, recombinant ARF6 serves as a vital tool to unravel its multifaceted functions and therapeutic potential in human diseases.
×
